Journal of Cardiac Failure
Volume 16, Issue 2 , Pages 121-127 , February 2010

Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension

  • Shannon E. Blalock

      Affiliations

    • Childrens Medical Center Dallas
    • Corresponding Author InformationReprint requests: Shannon Blalock, 1935 Medical Center Drive, Division of Cardiology, 3rd Floor, Dallas, TX 75235. Phone: (214) 456-6333; Fax: (214) 456-6154.
    • ,
  • Susan Matulevicius

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Laura C. Mitchell

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Sharon Reimold

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • John Warner

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Ronald Peshock

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Fernando Torres

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas
    • ,
  • Kelly M. Chin

      Affiliations

    • Parkland Hospital/UT Southwestern University Hospital, University of Texas Southwestern Medical Center at Dallas

Received 3 June 2009 ,Revised 30 August 2009 ,Accepted 29 September 2009.

References 

  1. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):62S–67S
  2. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010–3019
  3. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529–535
  4. Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson. 1999;1:7–21
  5. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28:1250–1257
  6. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780–788
  7. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124:247–254
  8. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27:589–595
  9. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244–249
  10. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477–1482
  11. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343–349
  12. Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, Bronzwaer JG, Marques KM, Postmus PE, et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest. 2004;125:572–579
  13. Hinderliter AL, Willis PWT, Barst RJ, Rich S, Rubin LJ, Badesch DB, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 1997;95:1479–1486
  14. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:1380–1386
  15. Chin KM, Kingman M, de Lemos JA, Warner JJ, Reimold S, Peshock R, et al. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. Am J Cardiol. 2008;101:1669–1672
  16. Reesink HJ, Marcus JT, Tulevski II, Jamieson S, Kloek JJ, Vonk Noordegraaf A, et al. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg. 2007;133:58–64
  17. Kasimir MT, Seebacher G, Jaksch P, Winkler G, Schmid K, Marta GM, et al. Reverse cardiac remodelling in patients with primary pulmonary hypertension after isolated lung transplantation. Eur J Cardiothorac Surg. 2004;26:776–781
  18. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J. 2004;147:218–223
  19. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114:1883–1891

 Supported by Grant Number UL1RR024982 and KL2RR024983, titled, “North and Central Texas Clinical and Translational Science Initiative” (Milton Packer, MD, PI) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp.

 Dr. Torres has served as a speaker/consultant and has received research grants from Gilead, which makes ambrisentan. Dr. Chin has received research grants from Gilead and has served as a speaker/consultant for Actelion and United Therapeutics.

PII: S1071-9164(09)01092-6

doi: 10.1016/j.cardfail.2009.09.008

Journal of Cardiac Failure
Volume 16, Issue 2 , Pages 121-127 , February 2010

Article Tools

* Image Usage & Resolution